Amnion-derived cell compositions, methods of making and uses thereof

• US 8,741,646 B2
• Filed: 10/06/2011
• Issued: 06/03/2014
• Est. Priority Date: 03/31/2005
• Status: Active Grant

• Current Assignee: Stemnion, Inc.
• Original Assignee: Stemnion, Inc.
• Inventors: Emig, Charlotte A, Marshall, Vivienne S
• Primary Examiner(s): Driscoll, Lora E Barnhart
• Application Number:
  US13/317,001
• Publication Number:
  US 20120270319A1
• Time in Patent Office: 971 Days
• Field of Search: None
• US Class Current: 435/405
• CPC Class Codes: A61K 2800/10 General cosmetic use
• CPC Class Codes: A61K 35/12 Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells vaccines or medicinal preparations containing antigens or antibodies A61K39/00
• CPC Class Codes: A61K 35/50 Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
• CPC Class Codes: A61K 8/982 Reproductive organs; Embryos, Eggs
• CPC Class Codes: A61Q 19/00 Preparations for care of the skin
• CPC Class Codes: C12N 2501/11 Epidermal growth factor [EGF]
• CPC Class Codes: C12N 2502/02 embryonic cells
• CPC Class Codes: C12N 5/0605 Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
• CPC Class Codes: C12N 5/0629 Keratinocytes; Whole skin

Abstract

The invention is directed to substantially purified amnion-derived cell populations, compositions comprising the substantially purified amnion-derived cell populations, and to methods of creating such substantially purified amnion-derived cell populations, as well as methods of use. The invention is further directed to antibodies, in particular, monoclonal antibodies, that bind to amnion-derived cells or, alternatively, to one or more amnion-derived cell surface protein markers. The invention is further directed to methods for producing the antibodies, methods for using the antibodies, and kits comprising the antibodies.

Claims

1. A composition comprising conditioned media, wherein the conditioned media is made by a method comprising the steps of

a) obtaining a placenta and isolating an amnion from the placenta,

b) enzymatically releasing amnion-derived epithelial cells from the amnion,

c) collecting the released amnion-derived epithelial cells,

d) culturing the collected amnion-derived epithelial cells of step (c) in basal culture medium that is supplemented with human serum albumin and recombinant human EGF;

e) removing the culture medium after about 2-3 days and applying fresh culture medium; and

f) collecting the culture medium after culturing the cells for 2-3 days.

2. The composition of claim 1 wherein steps (e) and (f) are repeated a plurality of times.

3. The composition of claim 1 wherein the basal medium is IMDM.

4. The composition of claim 3 wherein the IMDM is supplemented with 0.5% human serum albumin.

5. The composition of claim 1 wherein the recombinant human EGF is at a concentration of 10 ng/mL of culture medium.

6. The composition of claim 1 wherein the collected cells of step c) are negative for expression of the protein markers CD90, CD117 and CD105.